FREQUENCY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ITS ASSOCIATION WITH DIABETES MELLITUS, HYPERTENSION AND CHOLELITHIASIS AMONG PATIENTS UNDERGOING ROUTINE ULTRASONOGRAPHY
DOI:
https://doi.org/10.59058/jaimc.v20i2.36Keywords:
Cholelithiasis, Diabetes Mellitus, Hypertension, NAFLD, UltrasoundAbstract
Objective: To find the frequency of non-alcoholic fatty liver disease (NAFLD) and its association with diabetes mellitus, hypertension and cholelithiasis.
Methods: This was a cross-sectional study conducted in department of radiology, Sughra Shafi Medical Complex, Narowal. About 545 subjects who fulfilled the inclusion criteria were included through nonprobability/ convenient sampling technique. Abdominal ultrasound of every participant was conducted to determine frequency of NAFLD among sample size. A structured questionnaire consisting of demographic details and comorbidities was designed. Diabetic, and hypertensive status was determined on patient’s history and choleli-thiasis was assessed on ultrasonography. Data were entered in SPSS 21 software and presented as frequency and percentages.
Results: Among 545 patients there were 282 (51.7%) male and 263 (48.3%) female participants with mean age of 48.56 ± 3.67 years SD. The overall frequency of NAFLD in the sample size was 39.8%. Diabetes was found in 115 (21.1%) participants, NAFLD was present in 44(64.7%) diabetic males and 29 (25.2%) diabetic females. Hypertension was found in 92 (16.9%) participants, NAFLD was present in 30(32.6%) hypertensive males and 24 (61.5%) hypertensive females. Cholelithiasis was found in 18 (8.0%) patients NAFLD was present in 30(32.6%) hypertensive males and 24 (61.5%) hypertensive females. There was no statistical significant difference among gender and presence of NAFLD. (P>0.05)
Conclusion: It is concluded that on ultrasound NAFLD is a common finding and it is associated with diabetes mellitus, hypertension and cholelithiasis.
References
Qayyum A, Nystrom M, Noworolski SM, Chu P, Mohanty A, Merriman R. MRI steatosis grading: development and initial validation of a color Mapping system. AJ RAm JRoentgenol. 2012;198(3):582–8
N. M.De Alwis, C.P.Day. Non-alcoholic fatty liver disease: The Mist gradually clears. J Hepatol 2008; 48: 4-12.
Chalasani N,Younossi Z,Lavine JE, etal. The diagnosis and Management of non-alcoholic fatty liver disease: practice guideline By the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterolo- gical Association. Hepatology. 2012; 55(6):2005– 23.
Adams LA,Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22(9): 1129– 33
Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steato hepatitis: Summary of an AASLD Single Topic Conference. Hepatology. 2003; 37(5):1202–19.
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCulloughAJ. Nonalcoholic fatty liver disease: a spectrum of Clinical and pathological severity. Gastroenterology. 1999;116(6):1413–19.
Bhala N, Angulo P, vander PoortenD, et al. The natural history of non-Alcoholic fatty liver disease with advan- ced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54(4):1208–16
Ndumele CE, Nasir K, Conceiçao RD, Carvalho JA, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic infla- mmation. Arterioscler Thromb Vasc Biol. 2011; 31(8): 1927–32.
Bullock RE, Zaitoun AM,Aithal GP, Ryder SD, Beckingham IJ,Lobo DN.association of non-alcoholic steato hepatitis without significant fibrosis with hepato- cellular carcinoma. J Hepatol. 2004;41(4):685–86.
Kurosaki M, Hosokawa T, Matsunaga K,etal. Hepatic steatosis In chronic hepatitis C is a significant risk factor for developing Hepatocellular carcinoma inde- pendent of age, sex, obesity, fibrosis Stage and response to interferon therapy. Hepatol Res. 2010;40(9):870– 77
Önnerhag K, Nilsson PM, Lindgren S. Increased risk of cirrhosis and hepatocellular cancer during long- term follow-up of patients with biopsy- proven NAFLD. Scand J Gastroenterology. 2014;49(9):1111– 18.
Koplay M, Sivri H. Erdogan H. Importance of imaging and recent developments in diagnosis of non-alcoholic fatty liver disease.WorldJHepatol.2015; 7: 769-76.
Troiano RP, Berrigan D, Dodd KW,Mâsse LC,Tilert T, McDowell M. Physical activity in the United States measured by accelerometer. Med Sci SportsExerc. 2008;40(1):181–88.
Chalasani N, Younossi Z, Lavine JE, et al. The diag- nosis and Management of non-alcoholic fatty liver disease: practice guideline By the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroentero- logical Association. Hepatology. 2012; 55(6): 2005
Butt AS. Epidemiology of Viral Hepatitis and Liver Diseases in Pakistan. Euroasian JHepato- Gastroente- rol2015;5(1):43-8.
Sample size calculator. [online]. Available from: URL: www.raosoft.com/samplesize.htm
Ando Y, Jou J. Nonalcoholic Fatty Liver Disease and Recent Guideline Updates. Clinical Liver Disease, 2021; 17(1), 23-28.
Sudhir Navale, Dhruv Vala, Madhavi Gupta. Grading of Non-alcoholic fatty liver disease on ultrasound and its correlation with lipid profile. Intern J Contemporary Med Surg and Radiol. 2019;4(3):C187-C192
Shah AS, Khan S, Rahim H, Chishti KA, Khan AG. Prevalence of non alcoholic fatty liver and Non alco- holic Steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa, Pakistan. Pak J Pharm Sci. 2018 Jan; 31(1):193-198.https://pubmed.ncbi.nlm.nih.gov/ 29348103/
Abdul Ghani, R, Raja M, Zafar M, Jabeen S, Naqvi S, Raja G. Identification of Metabolic risk phenotypes predisposing to Non-Alcoholic Fatty Liver Disease in a Pakistani Cohort. Pak J Med Sci. 2017; 33(1). doi: 10.12669/pjms.331.11445
Zubair R, Mirza M, Iftikhar J, Saeed N. Frequency of incidental fatty liver on ultrasound and its association with diabetes mellitus and hypertension. Pak J Med Sci. 2018; 34(5). doi: 10.12669/pjms.345.15102
Taseer IH, Hussain L, Safdar S, Mirbahar AM, Ahmad
I. Frequecy of non- alcoholic fatty liver disease (NAFLD) & its biochemical derangements in Type- 2 diabetic patients. Pak J Med Sci 2009; 25950:817- 20.
Almahmoud M, Al Khawaja N, Alkinani A, Khader Y, Ajlouni, K. Prevalence of fatty liver disease and its associated factors among Jordanian patients with type 2 diabetes mellitus: A cross-sectional study. Annals of Medicine and Surgery,] 2021; 68, 102677. doi: 10.1016/j.amsu.2021.102677
Lau, K, Lorbeer R, Haring R., Schmid C, Wallaschofski H, Nauck, M. et al. The association between fatty liver disease and blood pressure in a population-based pros- pective longitudinal study. Journal of Hypertension, 2010; 28(9): 1829-35.
López-Suárez ., Guerrer, J, Elvira-González J, Beltrán- Robles M, Cañas-Hormigo F, Bascuñana- Quirell A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and non- hypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroen- terol Hepatol. 2011;23(11):1011-7
Lee Y, Wu J, Yang Y, Chang C, Lu F, Chang C. Mode- rate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease. Scandinavian J Gastroenterol. 2014; 49(8): 1001-
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 JAIMC
This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published in this journal come under creative commons licence Attribution 4.0 International (CC BY 4.0) which allows to copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially under following terms.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The editorial board of the Journal strives hard for the authenticity and accuracy of the material published in the Journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board. Many software like (Google Maps, Google Earth, Biorender (free version)) restricts the free distribution of materials prepared using these softwares. Therefore, authors are strongly advised to check the license/copyright information of the software used to prepare maps/images. In case of publication of copyright material, the correction will be published in one of the subsequent issues of the Journal, and the authors will bear the printing cost.
